David E. Olson, PhD
Co-Founder, Chief Innovation Officer, Head of the SAB
Prof David E. Olson, PhD studied chemistry and neuroscience at Stanford University and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. His academic lab at the University of California, Davis discovered that psychedelics promote structural and functional neuroplasticity in the cortex. They coined the term “psychoplastogen” to describe small molecules that produce rapid and long-lasting psychedelic- and ketamine-like effects on neuronal structure, and they invented the first non-hallucinogenic psychoplastogens capable of producing sustained therapeutic effects in preclinical models after a single dose.